Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Carcinoma, Transitional Cell 25Urinary Bladder Neoplasms 23Ureteral Neoplasms 8Urologic Neoplasms 4Urethral Neoplasms 3Parkinson Disease 4, Autosomal Dominant Lewy Body 3Neoplasms 3Neoplasm Metastasis 3Urogenital Neoplasms 2Muscle Invasive Bladder Urothelial Carcinoma 2Metastatic Urothelial Cancer 2Carcinoma, Renal Cell 2Carcinoma, Non-Small-Cell Lung 2Breast Neoplasms 2Advanced Bladder Cancer 2Urothelial Cancer 1Urologic Diseases 1Urogenital Diseases 1Urinary Bladder Diseases 1Urachal adenocarcinoma 1Triple Negative Breast Neoplasms 1Salivary Gland Neoplasms 1Renal Pelvis and Ureter Urothelial Carcinoma 1Peripheral Nervous System Diseases 1Penile Squamous Cell Carcinoma (PSCC) 1Penile Neoplasms 1Pancreatic Neoplasms 1Non-Muscle Invasive Bladder Neoplasms 1Neoplasms by Site 1Muscle-invasive Bladder Cancer 1

Interventions

Acupuncture Therapy 10Exercise 7Cryotherapy 6Paclitaxel 5Glutamine 5Surveys and Questionnaires 3Duloxetine Hydrochloride 3Dexamethasone 3Bortezomib 3Acetylcysteine 3Thioctic Acid 2Tablets 2Sodium Chloride 2Saline Solution 2Physical Therapy Modalities 2Low-Level Light Therapy 2Lenalidomide 2Fish Oils 2Fatty Acids, Omega-3 2ziconotide 1sagopilone 1pembrolizumab 1nicotinamide-beta-riboside 1nabilone 1glutamic acid diethyl ester 1eribulin 1enfortumab vedotin 1allantoicase 1Yoga 1XELOX 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Peripheral Nervous System Diseases × enfortumab vedotin × Clear all
NCT07484022 2026-06-03

Study of GB-4362 With Enfortumab Vedotin and Pembrolizumab for Advanced Urothelial Cancer

Generate Biomedicines

Phase 1 Recruiting
37 enrolled
Genitourinary

Carcinoma, Transitional Cell, Peripheral Nervous System Diseases

Data powered by HemOnc (CC BY 4.0) Colophon âš¡